Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

Proceedings of the National Academy of Sciences(2023)10.1073/pnas.2313137120Source: DataRank Database

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status is a research paper published in Proceedings of the National Academy of Sciences (2023). On theSindex it has a DataRank of 0. It has been cited 29 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access29 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 2.63)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Heidi M. Vieira ORCID,Chaitra Rao ORCID,Jacob M. Hughes ORCID,Zaria Beckley,Dianna H. Huisman ORCID

Live enrichment

PubMed:37972068 PMC:PMC10666034 OpenAlex:https://openalex.org/W4388728297

HHS | NIH | Office of Extramural Research, National Institutes of Health

Grant: CA255232

HHS | NIH | Office of Extramural Research, National Institutes of Health

Grant: CA267515

HHS | NIH | Office of Extramural Research, National Institutes of Health

Grant: GM121316

HHS | NIH | Office of Extramural Research, National Institutes of Health

Grant: CA268766

DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs

Grant: LC180213

DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs

Grant: LC210123

Nebraska Department of Health and Human Services

Grant: LB506

Nebraska Department of Health and Human Services

Grant: LB606

Boehringer Ingelheim

Grant: CRADA

HHS | NIH | Office of Extramural Research, National Institutes of Health

Grant: T32CA009476

NCI NIH HHS

Grant: F30 CA268766

NIGMS NIH HHS

Grant: P20 GM121316

NCI NIH HHS

Grant: R01 CA255232

NCI NIH HHS

Grant: R21 CA267515

National Institutes of Health

Grant: 5P20GM121316-03

Nebraska Center for Molecular Target Discovery and Development

National Institutes of Health

Grant: 5R01CA255232-02

Isoform-specific signaling as a determinant of RAS-driven oncogenesis

National Institutes of Health

Grant: 1F30CA268766-01A1

Molecular control of tumor-initiating cells in Ras-driven cancers

National Institutes of Health

Grant: 5R21CA267515-02

Preventing Therapeutic Resistance in RAS-mutated Pediatric Cancers

National Institutes of Health

Grant: 5T32CA009476-11

CANCER BIOLOGY TRAINING PROGRAM

FWCI

2.63

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10666034/pdf/pnas.202313137.pdf

publisherhttps://pnas.org/doi/pdf/10.1073/pnas.2313137120

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10666034

journalhttps://doi.org/10.1073/pnas.2313137120

Fields of Study

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK PathwaysLung Cancer Treatments and Mutations0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HumansMutationProtein KinasesColorectal NeoplasmsProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesReceptor Protein-Tyrosine KinasesSOS1 ProteinMitogen-Activated Protein Kinase KinasesMAP Kinase Kinase KinasesCell Line, TumorProtein Kinase InhibitorsClass I Phosphatidylinositol 3-Kinases

Keywords

TrametinibKRASMEK inhibitorCancer researchMAPK/ERK pathwayBiologyKinaseCancerCell biologyColorectal cancerGeneticsResistanceRasKsr1Sos1Mitogen-Activated Protein Kinase KinasesClass I Phosphatidylinositol 3-KinasesReceptor Protein-Tyrosine KinasesBiological SciencesMAP Kinase Kinase KinasesProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesCell Line, TumorMutationHumansColorectal NeoplasmsSOS1 ProteinProtein Kinase InhibitorsProtein Kinases

Sustainable Development Goals

SDG 0: Good health and well-being